# Livzon Pharmaceutical Group Inc. clinical trials: 28 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 28 trials with Livzon Pharmaceutical Group Inc. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Livzon Pharmaceutical Group Inc.: 28 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/livzon-pharmaceutical-group-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 28
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 28, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 5, 2026 | NCT07746479 | A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis ) | Livzon Pharmaceutical Group Inc. | Phase 3 | Completed | Psoriasis | 244 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746479) |
| May 9, 2025 | NCT06963320 | Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty | Livzon Pharmaceutical Group Inc. | Phase 2 | Recruiting | Circulatory Disease | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06963320) |
| February 27, 2025 | NCT06850480 | A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis | Livzon Pharmaceutical Group Inc. | Phase 3 | Recruiting | Reflux Esophagitis (RE) | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06850480) |
| November 1, 2023 | NCT06110676 | A Study to Evaluate the Efficacy and Safety of LZM012 | Livzon Pharmaceutical Group Inc. | Phase 3 | Unknown | Psoriasis | 918 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06110676) |
| May 3, 2023 | NCT05841394 | A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole... | Livzon Pharmaceutical Group Inc. | Phase 3 | Completed | Stress Ulcer Bleeding | 449 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05841394) |
| October 19, 2022 | NCT05585567 | A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5 | Livzon Pharmaceutical Group Inc. | Early phase 1 | Unknown | COVID-19 Pandemic | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05585567) |
| October 17, 2022 | NCT05583357 | Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351 | Livzon Pharmaceutical Group Inc. | Early phase 1 | Unknown | COVID-19 Pandemic | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05583357) |
| March 10, 2022 | NCT05273528 | The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine | Livzon Pharmaceutical Group Inc. | Phase 2 | Unknown | COVID-19 Pandemic | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05273528) |
| February 15, 2022 | NCT05239832 | Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity | Livzon Pharmaceutical Group Inc. | Phase 2 | Unknown | COVID-19 Pandemic | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05239832) |
| February 14, 2022 | NCT05238649 | Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine | Livzon Pharmaceutical Group Inc. | Phase 2 | Unknown | COVID-19 Pandemic | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05238649) |
| November 18, 2021 | NCT05125874 | Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization | Livzon Pharmaceutical Group Inc. | Not applicable | Unknown | COVID-19 Pandemic | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05125874) |
| October 27, 2021 | NCT05096845 | Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III | Livzon Pharmaceutical Group Inc. | Phase 3 | Unknown | COVID-19 Pandemic | 22,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05096845) |
| October 27, 2021 | NCT05096832 | Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study | Livzon Pharmaceutical Group Inc. | Phase 3 | Completed | COVID-19 Pandemic | 10,381 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05096832) |
| September 20, 2021 | NCT05050474 | Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) | Livzon Pharmaceutical Group Inc. | Phase 1 | Completed | COVID19 | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05050474) |
| July 19, 2019 | NCT04026321 | Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in... | Livzon Pharmaceutical Group Inc. | Phase 1 | Completed | Solid Tumor Refractory to Standard Therapy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04026321) |
| March 7, 2018 | NCT03456609 | Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Patients(BCS) With Digestive Tract . | Livzon Pharmaceutical Group Inc. | Not applicable | Unknown | Carcinogenic Fatigue | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03456609) |
| March 6, 2018 | NCT03455205 | Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Chemo Patients With Digestive Tract . | Livzon Pharmaceutical Group Inc. | Not applicable | Unknown | Digestive Tract | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03455205) |
| December 5, 2017 | NCT03362281 | Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients | Livzon Pharmaceutical Group Inc. | Phase 3 | Completed | Peptic Ulcer Hemorrhage | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03362281) |
| December 5, 2017 | NCT03362268 | IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients | Livzon Pharmaceutical Group Inc. | Phase 2 | Completed | Peptic Ulcer Hemorrhage | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03362268) |
| September 18, 2017 | NCT03286296 | LZM009 to Treat Patients With Advanced Solid Tumors | Livzon Pharmaceutical Group Inc. | Phase 1 | Completed | Solid Tumor | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03286296) |
| August 19, 2016 | NCT02873065 | Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori | Livzon Pharmaceutical Group Inc. | Phase 4 | Completed | Helicobacter Pylori Eradication | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02873065) |
| August 9, 2016 | NCT02860624 | Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients | Livzon Pharmaceutical Group Inc. | Phase 3 | Completed | Gastroesophageal Reflux Disease | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02860624) |
| July 28, 2016 | NCT02847455 | Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients | Livzon Pharmaceutical Group Inc. | Phase 2/3 | Completed | Duodenal Ulcer | 408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02847455) |
| July 18, 2016 | NCT02835560 | Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection | Livzon Pharmaceutical Group Inc. | Phase 4 | Completed | Helicobacter Pylori Eradication Antibiotic | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02835560) |
| December 4, 2014 | NCT02307994 | Clinical Research on Effectiveness and Safety of Treatment of Severe Oligospermia or Azoospermia With uFSH | Livzon Pharmaceutical Group Inc. | Phase 4 | Unknown | Oligospermia, Azoospermia | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02307994) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 2 |
| Phase 1 | 3 |
| Phase 2 | 7 |
| Phase 2/3 | 1 |
| Phase 3 | 9 |
| Phase 4 | 3 |
| Not applicable | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 14 |
| Unknown | 12 |
| Recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| COVID-19 | 9 |
| Duodenal Ulcer | 3 |
| Psoriasis | 2 |
| Gastroesophageal Reflux | 2 |
| Peptic Ulcer Hemorrhage | 2 |
| Esophagitis, Peptic | 1 |
| Oligospermia | 1 |
| Azoospermia | 1 |
| Infertility | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Window suppliers in the United States](https://specstream.ai/data/businesses/window-suppliers/united-states)
- [Property management companies in the United States](https://specstream.ai/data/businesses/property-management-companies/united-states)
- [Investment management firms in the United States](https://specstream.ai/data/businesses/investment-management-firms/united-states)
- [Dim sum restaurants in the United States](https://specstream.ai/data/businesses/dim-sum-restaurants/united-states)
- [Art restoration companies in the United States](https://specstream.ai/data/businesses/art-restoration-companies/united-states)
